SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001178913-19-001246
Filing Date
2019-04-29
Accepted
2019-04-29 13:58:12
Documents
2
Group Members
CATALYST CEL FUND L.P.CEL CATALYST CHINA ISRAEL FUND L.P.CEL CATALYST CHINA ISRAEL GENERAL PARTNER LTD

Document Format Files

Seq Description Document Type Size
1 SC 13G/A zk1922970.htm SC 13G/A 165949
2 EXHIBIT A exhibit_a.htm EX-99 41494
  Complete submission text file 0001178913-19-001246.txt   209319
Mailing Address 950 WINTER STREET WALTHAM MA 02451
Business Address 950 WINTER STREET WALTHAM MA 02451 (858) 909-0749
Eloxx Pharmaceuticals, Inc. (Subject) CIK: 0001035354 (see all company filings)

IRS No.: 841368850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-56243 | Film No.: 19775090
SIC: 8731 Services-Commercial Physical & Biological Research

Mailing Address 28 HAARBAA ST. TEL AVIV L3 6473925
Business Address 28 HAARBAA ST. TEL AVIV L3 6473925 972-3-6950666
Catalyst CEL Management Ltd. (Filed by) CIK: 0001726536 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3
Type: SC 13G/A